Skip to main content
AAN.com
×
Site maintenance Tuesday, June 24, 2025. Please note that new registrations and purchases will be unavailable on this date.
Article
May 5, 2021
Open AccessLetter to the Editor

Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
A Registry-Based Study

June 15, 2021 issue
96 (24) e2956-e2965
Letters to the Editor
7 September 2021
Author Response: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
Hong Xu, MD PhD| Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet
Sara Garcia-Ptacek, MD PhD| Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet
Bengt Lindholm, MD PhD| Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
Maria Eriksdotter, MD PhD| Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet
Juan Jesus Carrero, Pharm, PhD| Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet

We thank Dr. Fischereder for the comments on our study.1 Our goal was to explore the association between kidney function and the risk of dementia, not to imply causation. While underlying mechanisms remain unclear, they do not preclude our findings from being plausible. Subsequent studies confirm an association between cognitive impairment and markers of kidney dysfunction.2,3 Experimental evidence suggests that uremia-induced chronic inflammation, oxidative stress, hypercoagulation, vitamin-D deficiency, klotho deficiency, hyperparathyroidism, anemia, and impaired peripheral amyloid-β clearance may lead to dementia.4 Besides, chronic kidney disease (CKD) may be a risk mediator for other conditions that cause dementia, such as smoking, hypertension, diabetes, and lipid disorders.4 It is important to note that our study reported similar associations in persons with and without diabetes or hypertension.

The hypothesis regarding dementia risk in individuals with high glomerular filtration rate (GFR) is interesting, but impossible to dissect from our report. Individuals with high GFR may be persons with glomerular hyperfiltration, or with an illness that results in low muscle mass. Our findings cannot inform on dementia risks for kidney donors, though the procedure is not thought to have adverse long-term health effects, including on kidney function. Carefully conducted studies with 10-years of follow-up show a consistent rise in GFR during the first few years after kidney donation, followed by a GFR decline that appears slower than the GFR decline in controls.5 Regardless of whether kidney dysfunction is the cause or mediator, our research highlights a population likely to benefit from dementia screening.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.  

References

  1. Xu H, Garcia-Ptacek S, Trevisan M, et al. Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study [published online ahead of print, 2021 May 5]. Neurology. 2021;96(24):e2956-e2965. doi:10.1212/WNL.0000000000012113
  2. Scheppach JB, Coresh J, Wu A, et al. Albuminuria and Estimated GFR as Risk Factors for Dementia in Midlife and Older Age: Findings From the ARIC Study. Am J Kidney Dis. 2020;76(6):775-783. doi:10.1053/j.ajkd.2020.03.015
  3. Richard EL, McEvoy LK, Oren E, et al. Markers of Kidney Function and Longitudinal Cognitive Ability Among Older Community-Dwelling Adults: The Rancho Bernardo Study. J Alzheimers Dis. 2021;83(1):319-331. doi:10.3233/JAD-201605
  4. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain [published correction appears in Nat Rev Neurol. 2017 Oct 13;:]. Nat Rev Neurol. 2017;13(10):612-623. doi:10.1038/nrneurol.2017.111
  5. Goyal N, Levey AS. GFR after kidney donation: early recovery and subsequent decline. Kidney Int. 2020;98(1):57-59. doi:10.1016/j.kint.2020.04.025
29 June 2021
Reader Response: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
Michael Fischereder, Head, Renal Division| Medizinische Klinik IV, LMU-Klinikum

This registry-based analysis reports a strong correlation between renal function, estimated from a creatinine-based formula, and dementia.1 However, the pathological mechanism underlying this observation remains unclear. As direct effects of creatinine on cognitive function are highly unlikely, further discussion is needed to determine if causes or consequences of declining renal function are responsible for this association. In the case of reduced estimated glomerular filtration rate (eGFR) after living kidney donation from otherwise healthy individuals, such a differentiation is urgently needed. In later stages of chronic kidney disease, accumulation of unspecified uremic toxins may be one potential explanation—however, such a mechanism must be questioned at eGFR between 60 and 89 ml/min present in a large proportion of healthy individuals.

On the other hand, microvascular renal disease from Diabetes mellitus, smoking, or tobacco abuse accounts for approximately 50% of advanced chronic kidney disease. Among other comorbidities, diabetes mellitus, hypertension, and tobacco abuse are also significantly more prevalent with decreasing eGFR in this cohort. As outlined in the analysis of eGFR-decline, progressive renal injury is additionally associated with increasing risk for dementia. Another indicator towards a common cause for dementia and renal impairment is the increasing risk of dementia in individuals with eGFR > 105 ml/min, which may be found in diabetes mellitus. While the authors adjust their analyses for the above comorbidities statistically, it would be interesting to see a subgroup analysis evaluating if dementia is more prevalent in individuals who are free from Diabetes mellitus, hypertension, or tobacco abuse. Due to a potential increased risk for dementia, the ethical justification of living kidney donation should be questioned.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.  

References

  1. Xu H, Garcia-Ptacek S, Trevisan M, et al. Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study [published online ahead of print, 2021 May 5]. Neurology. 2021;96(24):e2956-e2965. doi:10.1212/WNL.0000000000012113

Information & Authors

Information

Published In

Neurology®
Volume 96Number 24June 15, 2021
Pages: e2956-e2965
PubMed: 33952656

Publication History

Received: November 6, 2020
Accepted: March 15, 2021
Published online: May 5, 2021
Published in issue: June 15, 2021

Permissions

Request permissions for this article.

Disclosure

B.L. is affiliated with Baxter Healthcare Corp. None of the other authors declare any conflict of interest pertinent to the present work. Go to Neurology.org/N for full disclosures.

Study Funding

Supported by the Swedish Research Council (2019-01059). H.X. is supported by a postdoctoral grant from Strategic Research program in Neuroscience at Karolinska Institutet.

Authors

Affiliations & Disclosures

From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
1) Loo and Hans Osterman foundation for medical research 2) Karolinska Institutet foundation for diseases of aging
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sara Garcia-Ptacek, MD, PhD
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Board member of Journal Perspectives in Neurology, from 2020, published by the Sociedad Española de Neurologia (Spanish Society of Neurology)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
FORTE, the Swedish Council for Health, Working Life and Welfare (dnr 2017-01646)
Research Support, Academic Entities:
1.
1) Loo and Hans Osterman foundation for medical research 2) Karolinska Institutet foundation for diseases of aging 3) StratNeuro 4) KI Foundations, KI central
Research Support, Foundations and Societies:
1.
1) Johanniterorden i Sverige/Swedish Order of St. John 2) The Gun and Bertil Stohne foundation 3) Postdoc funding from the Swedish Society for Medical Research 4) Swedish Stroke Association 5) Wenner-Gren travel stipend 6) The Spanish National Royal Academy of Medicine prize for doctorate in clinical medical sciences. 7) Foundation to the memory of Sigurd and Elsa Goljes Stock/Stock Options, Medical Equipment & Materials: AstraZeneca, Dynavax, Camurus
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marco Trevisan, Biostat
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marie Evans, MD, PhD
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
Astellas, Astra Zeneca,Vifor pharma (all commercial)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Astellas, payment for lectures. Vifor pharma,payment for lectures Astra zeneca, payment for lectures
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Stockholm Region, CIMED, 20180884, research Grant, 2019-2021 Stockholm Region ALF Medicin, 20180887 and 20200180 research Grant, 2019,2020, 2021
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Njurfonden
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bengt Lindholm, MD, PhD
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Bengt Lindholm is employed by Baxter Healthcare Corporation
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Bengt Lindholm is employed by Baxter Healthcare Corporation
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Baxter Novum is supported by a grant from Baxter Healthcare Corporation to Karolinska Institutet
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Baxter Healthcare Corporation
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Maria Eriksdotter, MD, PhD
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
Commercial entity Served as expert on two occasions for Biogen Inc Int advisory board Aug 26, 2020; 3 hrs Swe advisory board Nov 2, 2020 full day
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial entity. Lecture for staff working with elderly by Gothia fortbildning (Feb 2020) Non-Commercial entity: Honoraria for lecture and travel expenses for being invited speaker at the Swedish Dementia Days ( May 2019) Travel expenses for invited speaker at NIH, KI, UCL joint Neurosci symposium at Bethesda, MD, USA April 2019
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
MSD-not for this project/study
Research Support, Government Entities:
1.
Grants from the Regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet; Governmental grants for running the Swedish Dementia registry
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Swedish Brain Foundation ( not for this study)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Juan Jesus Carrero, Pharm, PhD
From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Department of Neurobiology, Care Sciences and Society, Department of Medical Epidemiology and Biostatistics (H.X., M.T., J.J.C.), and Division of Renal Medicine and Baxter Novum (M.E., B.L.), Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset; and Theme Aging (S.G.-P., M.E.), Karolinska University Hospital, Stockholm, Sweden.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Xu [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by KI Stiftelser och Fonder.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Predicting rapid kidney function decline in middle-aged and elderly Chinese adults using machine learning techniques, BMC Medical Informatics and Decision Making, 25, 1, (2025).https://doi.org/10.1186/s12911-025-03043-2
    Crossref
  2. Heterogeneous treatment effects of GLP‐1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real‐world target trial emulation, Alzheimer's & Dementia, 21, 6, (2025).https://doi.org/10.1002/alz.70313
    Crossref
  3. Uremic Toxins, CKD, and Cognitive Dysfunction, Journal of the American Society of Nephrology, 36, 6, (1208-1226), (2025).https://doi.org/10.1681/ASN.0000000675
    Crossref
  4. Generalized framework for identifying meaningful heterogenous treatment effects in observational studies: A parametric data-adaptive G-computation approach, Statistical Methods in Medical Research, 34, 4, (648-662), (2025).https://doi.org/10.1177/09622802251316969
    Crossref
  5. Long-Term Physical Exercise for Preventing CKD in Older Adults, Journal of the American Society of Nephrology, (2025).https://doi.org/10.1681/ASN.0000000636
    Crossref
  6. Association of body weight and serum uric acid with Alzheimer's disease biomarkers and cognitive impairment, Journal of Alzheimer’s Disease, 104, 1, (255-268), (2025).https://doi.org/10.1177/13872877251315011
    Crossref
  7. Quantifying Cognitive Function in Diabetes: Relationships Between AD8 Scores, HbA1c Levels, and Other Diabetic Comorbidities, Biomedicines, 13, 2, (340), (2025).https://doi.org/10.3390/biomedicines13020340
    Crossref
  8. The effect of creatinine level on amyloid-β and tau plasma concentrations in a cohort of Alzheimer’s disease patients without kidney disease, Behavioural Brain Research, 477, (115289), (2025).https://doi.org/10.1016/j.bbr.2024.115289
    Crossref
  9. Kidney replacement therapies in the older person: challenges to decide the best option, Clinical Kidney Journal, (2025).https://doi.org/10.1093/ckj/sfaf020
    Crossref
  10. Low preoperative estimated glomerular filtration rate level is a risk factor for postoperative cognitive dysfunction in elderly undergoing elective total hip replacement: a prospective observational study, Psychogeriatrics, 25, 1, (2025).https://doi.org/10.1111/psyg.13238
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text HTML

View Full Text HTML
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share